Anuh Pharma reported a 37.63% rise in net profit to Rs 11.42 crore for Q1 FY27. Revenue grew 3.93%, but a shift to high-value products and cost controls significantly boosted profitability.
Anuh Pharma's Q1 FY27 Profit Surges 37.6% to Rs 11.42 Cr
Anuh Pharma Q1 FY27 Profit: Rs 11.42 Cr | Anuh Pharma Q1 FY26 Profit: Rs 8.30 Cr Reader Takeaway: Profit growth outpaces revenue due to high-margin product shift; monitor customer concentration. ## What just happened Anuh Pharma reported a robust 37.63% year-on-year increase in net profit after tax (PAT) for the first quarter of FY27, reaching Rs 11.42 crore. This strong bottom-line performance was achieved despite a more modest 3.93% rise in operating revenue, which stood at Rs 193.81 crore. ## Why this matters The significant profit growth, which far outpaced revenue expansion, indicates improved operational efficiency and a successful strategic shift. Management attributes this to focusing on higher-value products for regulated markets, coupled with effective cost management and optimized asset utilization. ## The backstory The company operates with a manufacturing capacity of 2,400 MTPA at its Tarapur site, which includes multiple API and intermediate blocks. Anuh Pharma holds key regulatory clearances from USFDA and EU GMP, crucial for its growth in developed markets. ## What changes now Anuh Pharma aims for a steady annual growth of 15-20%. Future expansion will be driven by increased volumes in API lines, innovative processes, and diversification into new markets to mitigate currency risks. The company is debt-free. ## Risks to watch Investors should monitor customer concentration, as the top 5 clients accounted for 34% of sales in Q1 FY27. Reliance on specific regional markets, with 35.7% of export revenue from Asia, also presents a potential risk. ## Peer comparison As a mid-sized API manufacturer with aspirations in regulated markets, Anuh Pharma competes in a segment focused on quality, regulatory compliance, and cost-effectiveness. Its debt-free status and focus on high-margin products are key differentiators. ## Context metrics (time-bound) In Q1 FY27, Anuh Pharma's EBITDA was Rs 19.36 crore, a 41.56% increase YoY. Profit Before Tax (PBT) grew by 54.55% to Rs 16.93 crore. Production volume increased by 19.46% to 491 MT. ## What to track next Key areas to watch include the successful execution of the new product pipeline, the sustainability of improved margins, and strategies to diversify customer and geographic bases.
